Trials / Completed
CompletedNCT00904280
Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy of Numorphan® CR (Oxymorphone HCL Controlled Release) in Subjects With Cancer Pain or Chronic Lower Back Pain.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 239 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of oxymorphone ER as an analgesic in cancer and lower back pain subjects having chronic moderate to severe pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxymorphone ER | Open label |
Timeline
- Start date
- 2001-03-01
- Primary completion
- 2003-07-01
- Completion
- 2003-07-01
- First posted
- 2009-05-19
- Last updated
- 2009-05-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00904280. Inclusion in this directory is not an endorsement.